about
Influence of progestins on serum hormone levels in postmenopausal women with advanced breast cancer--I. General findingsCHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer[Breast cancer surgery in Norway 1990-95 illustrated by data from SINTEF United]Metabolic profiling of human brain metastases using in vivo proton MR spectroscopy at 3T.Outcome of whole-brain irradiation for breast cancer patients.Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancerMerging transcriptomics and metabolomics--advances in breast cancer profiling.Inflammation of mammary adipose tissue occurs in overweight and obese patients exhibiting early-stage breast cancerPredictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel.Cancer immunoediting from immunosurveillance to tumor escape in microvillus-formed niche: a study of syngeneic orthotopic rat bladder cancer model in comparison with human bladder cancer.In vivo MRS of locally advanced breast cancer: characteristics related to negative or positive choline detection and early monitoring of treatment response.Prognostic value of metabolic response in breast cancer patients receiving neoadjuvant chemotherapy.Feasibility of MR metabolomics for immediate analysis of resection margins during breast cancer surgeryMetabolic characterization of triple negative breast cancer.Progestins in breast cancer treatment. A review.Clinical pharmacokinetics of endocrine agents used in advanced breast cancer.Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer.Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer.The effect of exercise on fatigue and physical functioning in breast cancer patients during and after treatment and at 6 months follow-up: A meta-analysis.Comparison of toremifene and tamoxifen in post-menopausal patients with advanced breast cancer: a randomized double-blind, the 'nordic' phase III study.Metabolic profiles of brain metastases.Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survivalSerum concentrations of tamoxifen and its metabolites increase with age during steady-state treatment.Psychosocial interventions as part of breast cancer rehabilitation programs? Results from a systematic review.Everyday life in breast cancer survivors experiencing challenges: A qualitative study.Molecular Features of Subtype-Specific Progression from Ductal Carcinoma In Situ to Invasive Breast Cancer.Relative biological effectiveness of photon energies used in brachytherapy and intraoperative radiotherapy techniques for two breast cancer cell lines.Early effects of contemporary breast radiation on health-related quality of life - predictors of radiotherapy-related fatigue.A rat model of intravesical delivery of small interfering RNA for studying urinary carcinoma.Assessment of early docetaxel response in an experimental model of human breast cancer using DCE-MRI, ex vivo HR MAS, and in vivo 1H MRS.MR-determined metabolic phenotype of breast cancer in prediction of lymphatic spread, grade, and hormone status.Concomitant inactivation of the p53- and pRB- functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo.Erratum: Inflammation of mammary adipose tissue occurs in overweight and obese patients exhibiting early-stage breast cancer.Quantification of metabolites in breast cancer patients with different clinical prognosis using HR MAS MR spectroscopy.Multivariate modeling and prediction of breast cancer prognostic factors using MR metabolomics.Characterization of brain metastases using high-resolution magic angle spinning MRS.Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer.Oral high-dose progestins as treatment for advanced breast cancer.Pharmacokinetics and metabolism of medroxyprogesterone acetate in patients with advanced breast cancer.Hospital volume and prognosis among Norwegian breast cancer patients enrolled in adjuvant trials.
P50
Q28289771-9573402D-E137-4F53-AE65-296F52CD70DAQ28473504-7189224F-21CE-4082-9104-A04AF6426879Q30665203-E7AC5160-373B-4BC7-BB9E-B65106C9E696Q33292251-4A3674F6-FEC2-443A-94A7-0136701E8432Q33299697-7C3A25BA-8223-49B9-8BD6-60A3675F9CB9Q33611502-98FDD2A7-DC8F-4D77-921E-AD546B951C54Q33748176-62C16686-F469-4A07-88BB-EFF18A48C16CQ33767114-D705B362-CC52-469F-9709-E861E420D22DQ33893910-91AF6279-21DE-4BD0-9342-00E181A2E518Q33920324-0A626D99-F750-47BF-8A76-9604B1D46B05Q34016780-403FE914-7148-4517-9403-3E2E4EDFE0C1Q34140986-99A769CA-18ED-4694-A067-47DE697B7DB4Q34684585-C48408C5-F5BD-4A91-A76C-27702E8C0603Q34967995-50F42D54-4CA8-43A1-9F8D-C0E98F3C365BQ35651439-B5C8BC32-BCC8-4CE2-BE5E-9469FE148C62Q35722575-1E8CEC44-8BB8-40B7-BDCF-26593116CC16Q36138879-74E37F98-A413-421C-825F-CFC1F5AFD508Q36245541-B30BD8A1-9D07-4123-B576-C3D8FF3DABEEQ36348680-76A067F0-A099-4910-A7EC-40935A1F8CDAQ36422772-301A1816-41F7-4AF8-8E3E-635073D5CF62Q36590191-C194FEDB-631A-4F1A-8D65-6516981AB087Q36924468-39BD587F-6999-4652-AC19-4630C92C65ECQ37202495-31438ECC-542E-4D6F-8CE0-E11396971EEAQ37785918-95A66D82-15C2-4B06-8577-3DBC9B9B8370Q38676693-4197674B-8896-4E4F-BE72-CABEDC7984D8Q38843629-2EC38718-76A5-4FEA-A6CE-603F3081AC53Q39663945-62978EE1-B229-4CCC-85EF-AAA020EA101EQ39713922-380A5A62-1048-4583-BACA-E23F343F311EQ39717326-6842507C-8AE4-4066-8E57-7B7D5BA42FD8Q39817719-6D641CF5-1515-4701-B960-2CAB6F922521Q40276305-8043DFAC-08FF-42B2-AB88-DA91019188E9Q40907746-904F9452-F180-4DE3-8BC9-EFBDD4BEF94CQ42354091-1E49BE15-57A8-47DB-BD05-77EEEF47553DQ43184186-ECCB95C3-1106-4C24-B403-B3810742BC39Q43227553-9D4DB889-346D-4B3C-8FF5-7C7A9DE83D02Q43812454-4633AFBD-79C2-4F8A-BC44-D026A016272BQ43907492-27CFAF45-D137-43C3-A772-0381271A54A0Q44517936-D789A495-9E18-4805-8311-7DC76DB2AAC0Q44597303-F1EE95F4-548B-4605-9B55-7E733591B24BQ44680209-60BEEDB0-A5AE-420B-B03D-32937648D783
P50
description
Noors professor
@nl
Norwegian professor
@en
norsk professor
@nb
ollamh Ioruach
@ga
name
Steinar Lundgren
@ast
Steinar Lundgren
@da
Steinar Lundgren
@de
Steinar Lundgren
@en
Steinar Lundgren
@es
Steinar Lundgren
@fr
Steinar Lundgren
@ga
Steinar Lundgren
@nb
Steinar Lundgren
@nl
Steinar Lundgren
@nn
type
label
Steinar Lundgren
@ast
Steinar Lundgren
@da
Steinar Lundgren
@de
Steinar Lundgren
@en
Steinar Lundgren
@es
Steinar Lundgren
@fr
Steinar Lundgren
@ga
Steinar Lundgren
@nb
Steinar Lundgren
@nl
Steinar Lundgren
@nn
prefLabel
Steinar Lundgren
@ast
Steinar Lundgren
@da
Steinar Lundgren
@de
Steinar Lundgren
@en
Steinar Lundgren
@es
Steinar Lundgren
@fr
Steinar Lundgren
@ga
Steinar Lundgren
@nb
Steinar Lundgren
@nl
Steinar Lundgren
@nn
P1006
P214
P1006
P101
P2038
Steinar_Lundgren
P21
P214
P2287
P27
P31
P496
0000-0001-6121-5118
P6634
steinar-lundgren-3a01374a
P734
P735
P7859
viaf-288113177